MASATAKA TSUGE

Last Updated :2023/12/05

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medical), Associate Professor
E-mail
tsugehiroshima-u.ac.jp
Self-introduction
My research is focused on viral hepatitis.

Basic Information

Major Professional Backgrounds

  • 2006/04/01, 2007/01/31, Viral Hepatitis Research Fundation of Japan, Research resident
  • 2007/02/01, 2007/03/31, Hiroshima University, Hospital, Reserch Associate
  • 2007/04/01, 2008/03/31, Hiroshima University, Hospital, Assistant Professor
  • 2008/04/01, 2021/03/31, Hiroshima University, Natural Science Center for Basic Research and Development, Assistant Professor
  • 1998/05/16, 1999/06/30, Hiroshima University, Medical Hospital, Clinical Resident
  • 1999/07/01, 1999/09/30, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Intern doctor
  • 1999/10/01, 2000/03/30, Hiroshima University, Medical Hospital, Clinical Resident
  • 2000/04/01, 2002/03/31, Shobara Red Cross Hospital, Physician
  • 2018/04/01, Hiroshima College of Rihabilitation, Part-time lecturer
  • 2007/04/01, Radiation Effects Research Foundation, Part-time researcher
  • 2021/04/01, 2023/02/28, Hiroshima University, Natural Science Center for Basic Research and Development, Lecturer

Educational Backgrounds

  • Hiroshima University, Japan, 2002/04, 2006/03
  • Hiroshima University, Faculty of Medicine, Japan, 1992/04, 1998/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Viral hepatitis

Affiliated Academic Societies

  • The Japanese Society for Virology, 2003
  • The Japanese Society of Internal Medicine, 1998
  • Japan Gastroenterological Endoscopy Society, 2000
  • The Japanese Society of Gastroenterology, 2000
  • Japanese Cancer Association, 2005
  • The Japan Society of Hepatology, 2002
  • Japanese Society of Molocular Medicine, 2005

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  2. 2023, Undergraduate Education, Intensive, Practice of Medicine II
  3. 2023, Liberal Arts Education Program1, 1Term, Introductory Seminar for First-Year Students
  4. 2023, Undergraduate Education, First Semester, Internal Medicine I
  5. 2023, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Gastroenterology
  6. 2023, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Gastroenterology
  7. 2023, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Gastroenterology
  8. 2023, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Gastroenterology

Research Activities

Academic Papers

  1. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15(8), 202304
  2. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
  3. Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 16(2), 250-253, 202304
  4. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study, HEPATOLOGY RESEARCH, 53(3), 196-207, 202303
  5. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22(1), 20221222
  6. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
  7. The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro, PLOS PATHOGENS, 18(3), 202203
  8. Serum miR-1 92-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B, PLOS ONE, 17(2), 20220214
  9. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37(3), 592-599, 202203
  10. Detection of hepatitis B core antibody (including IgM and IgA class antibodies), 62(増刊号8), 129-133, 200408
  11. G to A hypermutation of hepatitis B virus, HEPATOLOGY, 41(3), 626-633, 200503
  12. ★, A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5 ' flanking region of SMYD3 is a risk factor for human cancers, NATURE GENETICS, 37(10), 1104-1107, 200510
  13. ★, Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus, HEPATOLOGY, 42(5), 1046-1054, 200511
  14. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3867-3874, 200611
  15. Enhanced SMYD3 expression is essential for the prowth of breast cancer cells., Cancer Sci, 97(2), 113-118, 200602
  16. Dual effect of APOBEC3G on Hepatitis B virus, JOURNAL OF GENERAL VIROLOGY, 88, 432-440, 200702
  17. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine, HEPATOLOGY, 45(5), 1179-1186, 200705
  18. Successful treatment of an entecavir-resistant hepatitis B virus variant, JOURNAL OF MEDICAL VIROLOGY, 79(12), 1811-1817, 200712
  19. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells., Oncogene, 200711
  20. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 89, 2108-2113, 200809
  21. A Case of Fulminant Hepatic Failure Caused by Hepatitis E virus79117, Clinical Journal of gastroenterology, 1, 69-74, 200806
  22. The first Japanese case of COACH syndrome, HEPATOLOGY RESEARCH, 39(3), 318-323, 200903
  23. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C, GASTROENTEROLOGY, 136(5), 1796-1805, 200905
  24. Ecabet sodium induces neuronal nitric oxide synthase-derived nitric oxide synthesis and gastric adaptive relaxation in the human stomach, JOURNAL OF GASTROENTEROLOGY, 44(11), 1118-1124, 200911
  25. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 51(6), 1046-1054, 200912
  26. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection, HEPATOLOGY RESEARCH, 39(12), 1159-1168, 200912
  27. G-to-A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection, JOURNAL OF INFECTIOUS DISEASES, 199(11), 1599-1607, 200906
  28. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15(8), 1087-1097, 201012
  29. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15(2), 177-184, 2010
  30. G to A hypermutation of TT virus, VIRUS RESEARCH, 149(2), 211-216, 201005
  31. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91, 1854-1864, 201007
  32. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor, JOURNAL OF GENERAL VIROLOGY, 91, 1668-1677, 201007
  33. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3205-3211, 201008
  34. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53(3), 439-443, 201009
  35. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 45(12), 1488-1496, 201012
  36. Animal model for study of human hepatitis viruses, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(1), 13-18, 201101
  37. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54(3), 408-414, 201103
  38. Impact of Radiation and Hepatitis Virus Infection on Risk of Hepatocellular Carcinoma, HEPATOLOGY, 53(4), 1237-1245, 2011
  39. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54(5), 872-878, 201105
  40. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83(6), 1048-1057, 201106
  41. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54(6), 1094-1101, 201106
  42. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83(6), 981-988, 201106
  43. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54(3), 764-771, 201109
  44. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83(9), 1597-1607, 201109
  45. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54(3), 781-788, 201109
  46. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF VIRAL HEPATITIS, 18(10), E550-E560, 201110
  47. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region, HEPATOLOGY RESEARCH, 41(11), 1126-1131, 201111
  48. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55(1), 11-18, 201107
  49. A first case of hepatic angiosarcoma treated with recombinant interleukin-2, Hiroshima J. Med. Sci., 60(4), 91-6, 201112
  50. ★, Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6(8), 201108
  51. ★, Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice, JOURNAL OF INFECTIOUS DISEASES, 204(2), 224-228, 201107
  52. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 55(4), 306-310, 2012
  53. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17(8), 1551-1561, 201208
  54. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B, HEPATOLOGY RESEARCH, 42(2), 139-149, 201202
  55. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19(2), E126-E133, 201202
  56. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47(7), 834-844, 201207
  57. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56(2), 555-566, 201208
  58. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27(9), 1467-1472, 201209
  59. Migration to the pulmonary artery of nine metallic coils placed in the internal iliac vein for treatment of giant rectal varices.Wataru Yamasaki, Hideaki Kakizawa, Masaki Ishikawa, Shuji Date, ;Fuminari Tatsugami, Hiroaki Terada, Keiichi Masaki, Tomokazu Kawaoka, Masataka Tsuge, Hiroshi Aikata, Kazuaki Chayama, and Kazuo Awai.Acta Radiol.1(6),2012, Acta Radiol, 1(6), 201207
  60. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7(10), 201210
  61. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85(5), 789-798, 201305
  62. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62(7), 1055-1061, 201307
  63. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 48(7), 847-855, 201307
  64. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108(9), 1464-1472, 201309
  65. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48(10), 1188-1204, 201310
  66. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases, HEPATOLOGY RESEARCH, 43(11), 1182-1189, 201311
  67. Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy., J Gastroenterology, 48(6), 779-780, 201306
  68. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 8(12), E84226, 201312
  69. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441(1), 230-235, 201311
  70. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 44(3), 280-287, 201403
  71. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(4), 2105-2112, 2014
  72. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29(5), 1035-1042, 201405
  73. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44(7), 740-749, 201407
  74. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, HEPATOLOGY RESEARCH, 45(11), 1047-1054, 201511
  75. A case of syndrome of inappropriate secretion of antidiuretic hormone following transarterial embolization with cisplatin, 111(9), 1805-1810, 201409
  76. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21(9), E89-E97, 201409
  77. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, HEPATOLOGY RESEARCH, 44(12), 1259-1264, 201411
  78. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44(14), E447-E454, 201412
  79. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44(14), E420-E427, 201412
  80. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, 201412
  81. Serum interleukin-6 associated with hepatocellular carcinoma risk: A nested case-control study, INTERNATIONAL JOURNAL OF CANCER, 134(1), 154-163, 201401
  82. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61(130), 323-328, 2014
  83. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20(4), 369-375, 201504
  84. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22(2), 158-165, 201502
  85. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22(2), 166-174, 201502
  86. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70(3), 273-287, 201503
  87. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion, Clinical journal of gastroenterology, 7(4), 333-337, 201508
  88. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(4), 726-732, 2015
  89. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 47(3), 809-814, 2015
  90. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45(6), 656-662, 201506
  91. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45(6), 607-617, 201506
  92. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases, EUROPEAN JOURNAL OF RADIOLOGY, 84(8), 1540-1545, 201508
  93. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63(3), 554-563, 201509
  94. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(3), 619-627, 201503
  95. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21(4), 307-315, 2016
  96. Factors associated with the effect of interferon-alpha sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B, Hepatology research, 45(12), 1195-1202, 201512
  97. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, Hepatology Research, 46(8), 758-764, 201607
  98. ★, Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72(1), 91-102, 201601
  99. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 201605
  100. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213, 62-68, 201602
  101. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice, JOURNAL OF VIROLOGY, 89(19), 10087-10096, 201510
  102. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 87(11), 1913-1920, 201511
  103. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25(11), 3272-3281, 201511
  104. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus, HEPATOLOGY RESEARCH, 46(3), E146-E153, 201603
  105. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 201608
  106. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report, HEPATOLOGY RESEARCH, 46(7), 707-712, 201606
  107. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma., Journal of Computer Assisted Tomography, 40(4), 524-530, 2016
  108. ITPA polymorphism effects on decrease of hemoglobin during simeprevir, pegylated interferon and ribavirin combination treatment for chronic hepatitis C., Hepatology Research, 2016
  109. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon and ribavirin therapy for older patients with genotype 1 chronic hepatitis C., Hepatology Research, 47(3), E5-E13, 201703
  110. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
  111. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study, JOURNAL OF GASTROENTEROLOGY, 52(1), 113-122, 201701
  112. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214(11), 1687-1694, 20161201
  113. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89(4), 665-671, 2017
  114. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12(3), 20170302
  115. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 52(2), 253-262, 201702
  116. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 201703
  117. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32(3), 645-650, 201703
  118. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(4), 504-511, 2017
  119. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(6), 746-753, 201706
  120. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92(6), 335-346, 2017
  121. ARFI : a new non-invasive method for evaluation of liver fibrosis, Kanzo, 50(8), 467-469, 20090825
  122. The efficacy of sequential treatment with lamivudine and alpha-interferon in anti-HBe-negative chronic hepatitis B patients -Examination of HBsAg seroclearance-, Kanzo, 54(10), 720-722, 2013
  123. Universal hepatitis B vaccination : pros and cons, Kanzo, 50(10), 598-604, 20091025
  124. Universal vaccination of hepatitis B virus vaccine, Kanzo, 53(2), 117-130, 20120225
  125. A case of acute hepatitis C with hepatitis C virus (HCV) genotype 3a : discussion of IL28-B, Kanzo, 54(2), 120-127, 20130225
  126. A case of clonorchiasis complicated with the expansion of liver cyst, Nippon Shokakibyo Gakkai Zasshi, 110(3), 456-464, 20130305
  127. A case of intrahepatic splenosis after splenic rupture with difficulty in preoperative diagnosis, Kanzo, 54(5), 317-325, 20130525
  128. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, Journal of Hepatology, 51(6), 1046-1054, 200912
  129. A First Case of Hepatic Angiosarcoma Treated with Recombinant Interleukin-2, Hiroshima Journal of Medical Sciences, 60(4), 91-96, 201112
  130. A case of syndrome of inappropriate secretion of antidiuretic hormone following transarterial embolization with cisplatin, Nippon Shokakibyo Gakkai Zasshi, 111(9), 1805-1810, 2014
  131. Hepatitis B infection derived from a donor and de novo autoimmune hepatitis subsequent to pegylated-interferon treatment for recurrent hepatitis C after living-liver transplantation: A case report, Kanzo, 55(10), 604-611, 2014
  132. Analysis of the anti-viral effects with nucleot(s)ide analogues using human hepatocyte chimeric mouse, 229(1), 11-16, 20090404
  133. The analysis of the chronic hepatitis B patients who discontinued the treatments with nucleotide analogues, Gastroenterology, 53(3), 300-308, 201109
  134. Anti-viral effects of tenofovir for HBV mutants, 54(5), 575-581, 201205
  135. Effects of HBV infection on the interferon response in immunodeficient human hepatocyte chimeric mice, 58(2), 231-238, 201402
  136. Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice., Antimicrob Agents Chemother, 2017
  137. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients., J Med Virol, 2017
  138. A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon alpha-2a in a patient with chronic hepatitis B virus infection, Rinsho Shinkeigaku, 56(10), 672-677, 201610
  139. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, Hepatol Res, 46(12), 1256-1263, 201611
  140. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, Hepatol Res, 47(8), 767-772, 201707
  141. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, J Gastroenterol, 52(3), 366-375, 201703
  142. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy, J Gastroenterol, 2017
  143. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia, Clin J Gastroenterol, 2017
  144. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol, 2017
  145. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, Hepatol Res, 2017
  146. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, J Gastroenterol, 2017
  147. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol, 2017
  148. ★, Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, Antimicrob Agents Chemother, 61(6), 201706
  149. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Hepatol Res, 2017
  150. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, Clin J Gastroenterol, 10(2), 179-184, 2017
  151. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, J Gen Virol, 98(5), 1040-1047, 201705
  152. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98(5), 1040-1047, 201705
  153. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, HEPATOLOGY RESEARCH, 47(8), 767-772, 201707
  154. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 20170810
  155. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89(11), 1963-1972, 201711
  156. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10(2), 179-184, 2017
  157. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52(12), 1252-1257, 201712
  158. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 201801
  159. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48(1), 51-58, 201801
  160. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(2), 193-204, 201802
  161. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 201802
  162. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 201803
  163. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53(4), 548-556, 2018
  164. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94(4), 215-222, 2018
  165. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13(4), 2018
  166. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9), 201709
  167. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500(2), 152-157, 20180602
  168. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18, 20180604
  169. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99(8), 1058-1065, 201808
  170. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice, HEPATOLOGY RESEARCH, 48(10), 814-820, 201809
  171. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33(10), 1780-1786, 201810
  172. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90(12), 1834-1840, 201812
  173. Early experience of seven hepatocellular carcinoma cases treated with regorafenib, CLINICAL CASE REPORTS, 6(11), 2217-2223, 201811
  174. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 201812
  175. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525, 48-61, 201812
  176. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(13), 1118-1130, 201812
  177. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23(3), 239-248, 2018
  178. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 201904
  179. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
  180. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
  181. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23(8), 639-646, 2018
  182. Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection, VIRUSES-BASEL, 11(3), 20190315
  183. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 1(5), 516-534, 201509
  184. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9, 20190611
  185. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
  186. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 201907
  187. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(4), 341-346, 201908
  188. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9, 20190820
  189. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
  190. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55(2), 217-226, 202002
  191. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 202003
  192. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(2), 267-270, 202004
  193. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59(7), 941-944, 2020
  194. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients, LIVER CANCER, 9(2), 148-155, 202004
  195. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
  196. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
  197. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
  198. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  199. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 839-843, 202010
  200. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
  201. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors, ONCOLOGY, 98(10), 727-733, 202010
  202. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection, BMC GASTROENTEROLOGY, 20(1), 20200925
  203. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration, JOURNAL OF INFECTIOUS DISEASES, 222(7), 1165-1169, 20201001
  204. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98(11), 787-797, 202011
  205. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
  206. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B, JOURNAL OF GASTROENTEROLOGY, 55(10), 977-989, 202010
  207. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
  208. PNPLA3andHLA-DQB1polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication, JOURNAL OF GASTROENTEROLOGY, 55(12), 1162-1170, 202012
  209. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 202102
  210. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
  211. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 202102
  212. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study, JOURNAL OF GASTROENTEROLOGY, 52(1), 113-122, 2017
  213. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214(11), 1687-1694, 2016
  214. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89(4), 665-671, 2017
  215. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 52(2), 253-262, 2017
  216. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 2017
  217. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12(3), 2017
  218. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32(3), 645-650, 2017
  219. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(4), 504-511, 2017
  220. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C, HEPATOLOGY RESEARCH, 47(3), E5-E13, 2017
  221. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(6), 746-753, 2017
  222. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92(6), 335-346, 2017
  223. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98(5), 1040-1047, 2017
  224. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6), 2017
  225. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, HEPATOLOGY RESEARCH, 47(8), 767-772, 2017
  226. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 2017
  227. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9), 2017
  228. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89(11), 1963-1972, 2017
  229. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY, 66, 253A-253A, 2017
  230. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy, HEPATOLOGY, 66, 629A-629A, 2017
  231. Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, HEPATOLOGY, 66, 764A-764A, 2017
  232. TARDBP regulates HBV transcription and replication through interaction with the core promoter, HEPATOLOGY, 66, 784A-785A, 2017
  233. Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model, HEPATOLOGY, 66, 786A-786A, 2017
  234. Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice, HEPATOLOGY, 66, 789A-789A, 2017
  235. Hepatitis B virus up-regulates IL8 expression via endoplasmic reticulum stress and leads to suppress interferon responsiveness, HEPATOLOGY, 66, 800A-801A, 2017
  236. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52(12), 1252-1257, 2017
  237. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 2018
  238. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy (vol 53, pg 107, 2017), JOURNAL OF GASTROENTEROLOGY, 53(1), 161-162, 2018
  239. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48(1), 51-58, 2018
  240. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(2), 193-204, 2018
  241. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy, JOURNAL OF GASTROENTEROLOGY, 53(2), 247-257, 2018
  242. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 2018
  243. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 2018
  244. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53(4), 548-556, 2018
  245. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94(4), 215-222, 2018
  246. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13(4), 2018
  247. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500(2), 152-157, 2018
  248. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18, 2018
  249. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99(8), 1058-1065, 2018
  250. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice, HEPATOLOGY RESEARCH, 48(10), 814-820, 2018
  251. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33(10), 1780-1786, 2018
  252. Regulation of the Hepatitis B Virus Gene Expression and Replication By the Multi-Functional Protein Tardbp, HEPATOLOGY, 68, 318A-318A, 2018
  253. The Influence of Histone Methyltransferase SUV39h1 on Hepatitis B Virus-Related Hepatocarcinogenesis, HEPATOLOGY, 68, 328A-329A, 2018
  254. Prevalence of NS5A Resistance Associated Variants in NS5A Inhibitor Treatment Failures and an Effective Treatment for NS5A-P32 Deleted Hepatitis C Virus in Humanized Mice, HEPATOLOGY, 68, 384A-384A, 2018
  255. Efficacy of Glecaprevir and Pibrentasvir Treatment for Hepatitis C Virus Drug Resistance-Associated Variants in Humanized Mice, HEPATOLOGY, 68, 411A-412A, 2018
  256. Stereotactic Body Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Small Hepatocellular Carcinoma, HEPATOLOGY, 68, 544A-545A, 2018
  257. A Novel Jak3KORag2KO Chimeric Mouse Model for the Study of Hepatitis Virus Virology, HEPATOLOGY, 68, 587A-587A, 2018
  258. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, HEPATOLOGY, 68, 597A-597A, 2018
  259. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radio Therapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombus, HEPATOLOGY, 68, 847A-847A, 2018
  260. Efficacy and Safety of Edoxaban for Treatment of Portal Vein Thrombosis in Patients with Liver Cirrhosis, HEPATOLOGY, 68, 1159A-1160A, 2018
  261. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90(12), 1834-1840, 2018
  262. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 2018
  263. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525, 48-61, 2018
  264. Host genetic factors affecting NAFLD/ NASH-related HCC in the Japanese population, CANCER SCIENCE, 109, 719-719, 2018
  265. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(13), 1118-1130, 2018
  266. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23(3), 239-248, 2018
  267. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 2019
  268. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 2019
  269. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 2019
  270. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23(8), 639-646, 2018
  271. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study (vol 23, pg 639, 2018), ANTIVIRAL THERAPY, 23(8), 709-709, 2018
  272. Characterization of HBV kinetics during infection and treatment in primary human hepatocytes, JOURNAL OF HEPATOLOGY, 70(1), E702-E702, 2019
  273. Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection, VIRUSES-BASEL, 11(3), 2019
  274. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9, 2019
  275. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 2019
  276. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 2019
  277. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9, 2019
  278. UNDERSTANDING EARLY HBV KINETICS DURING INFECTION AND TREATMENT IN PRIMARY HUMAN HEPATOCYTES: A DATA-DRIVEN MATHEMATICAL MODELING APPROACH, HEPATOLOGY, 70, 178A-178A, 2019
  279. EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA, HEPATOLOGY, 70, 228A-228A, 2019
  280. THE IMPACT OF INTERFERON-FREE DIRECT-ACTING ANTIVIRALS ON CLINICAL OUTCOME AFTER CURATIVE TREATMENT FOR HEPATITIS C VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA, HEPATOLOGY, 70, 353A-354A, 2019
  281. GENETIC POLYMORPHISM OF IP-10, NOT IFNL4 OR HLA-DPS, AFFECTS LIVER INFLAMMATION IN CHRONIC HEPATITIS B PATIENTS, HEPATOLOGY, 70, 412A-413A, 2019
  282. TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA, HEPATOLOGY, 70, 520A-520A, 2019
  283. STEREOTACTIC BODY RADIATION THERAPY COMBINED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR SMALL HEPATOCELLULAR CARCINOMA., HEPATOLOGY, 70, 528A-528A, 2019
  284. PERMISSION OF HEPATITIS B VIRUS INFECTION IN Jak3KORag2KO MOUSE, HEPATOLOGY, 70, 617A-617A, 2019
  285. MODELING-BASED RESPONSE-GUIDED THERAPY UNDER GLECAPREVIR/PIBRENTASVIR MAY OPTIMIZE DURATION OF THERAPY IN PATIENTS WITH COMPENSATED CIRRHOSIS, HEPATOLOGY, 70, 931A-931A, 2019
  286. RESISTANCE ANALYSIS FOR GLECAPREVIR AND PIBRENTASVIR ON GENOTYPE 1b HEPATITIS C VIRUS INFECTION IN SUBGENOMIC REPLICON SYSTEMS AND HUMAN HEPATOCYTE TRANSPLANTED MICE, HEPATOLOGY, 70, 988A-989A, 2019
  287. DIFFERENTIAL EFFECTS OF HOST GENETIC FACTORS ON HCV PERSISTENCE ACCORDING TO HCV GENOTYPES, HEPATOLOGY, 70, 1008A-1008A, 2019
  288. ASSOCIATION OF FNDC5, PNPLA3 AND TM6SF2 POLYMORPHISMS WITH HEPATIC STEATOSIS IN NAFLD PATIENTS, HEPATOLOGY, 70, 1050A-1051A, 2019
  289. A COMPREHENSIVE ANALYSIS OF A WIDE RANGE OF LIVER DISEASES BY 16S rRNA SEQUENCING REVEALS CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN EACH ETIOLOGY, HEPATOLOGY, 70, 1163A-1164A, 2019
  290. INDEPENDENT IMPACT OF POLYMORPHISM IN IRF5 AS WELL AS STAT4 ON HBV-RELATED HEPATOCARCINOGENESIS, HEPATOLOGY, 70, 1190A-1190A, 2019
  291. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 2019
  292. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 2019
  293. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 2020
  294. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55(2), 217-226, 2020
  295. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 2020
  296. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59(7), 941-944, 2020
  297. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients, LIVER CANCER, 9(2), 148-155, 2020
  298. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 2020
  299. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 2020
  300. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 2020
  301. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B, JOURNAL OF GASTROENTEROLOGY, 55(10), 977-989, 2020
  302. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 2020
  303. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 2020
  304. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 2020
  305. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors, ONCOLOGY, 98(10), 727-733, 2020
  306. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection, BMC GASTROENTEROLOGY, 20(1), 2020
  307. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration, JOURNAL OF INFECTIOUS DISEASES, 222(7), 1165-1169, 2020
  308. PNPLA3andHLA-DQB1polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication, JOURNAL OF GASTROENTEROLOGY, 55(12), 1162-1170, 2020
  309. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98(11), 787-797, 2020
  310. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 2020
  311. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 2021
  312. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60(6), 829-837, 2021
  313. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein, LIVER CANCER, 10(2), 151-160, 202104
  314. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23, 2021
  315. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99(5), 327-335, 202104
  316. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
  317. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
  318. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
  319. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100(26), 20210702
  320. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60(13), 2047-2053, 2021
  321. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99(8), 507-517, 202107
  322. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99(8), 491-498, 202107
  323. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
  324. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
  325. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice, JOURNAL OF VIROLOGY, 95(14), 202107
  326. MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter, JOURNAL OF VIROLOGY, 95(15), 202108
  327. Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?, VIRUSES-BASEL, 13(10), 202110
  328. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection, LIVER INTERNATIONAL, 41(12), 2836-2848, 202112

Invited Lecture, Oral Presentation, Poster Presentation

  1. Monitoring serum HBV RNA is useful for predicting rebound of hepatitis after the discontinuation of nucleotide analogue therapy in chronic hepatitis B patients, Tsuge M,Murakami E,Imamura M,Abe H,Miki D,Hiraga N,Ochi H,Hayes CN,Kawakami Y,Chayama K, Eisuke Murakami, Michio Imamura, Hiromi Abe, Daiki Miki, Nobuhiko Hiraga, Hidenori Ochi, C. Nelson Hayes, Hiroiku Kawakami, Kazuaki Chayama, The 11th JSH Single Topic Conference, 2014/11/20, Without Invitation, English, Japan Society of Hepatology, Hiroshima
  2. The incidences of HBsAg seroclearance and hepatocellular carcinoma in HBV carriers, 2015/04/25, Without Invitation, Japanese, Japanese Society of Gastroenterology, Tokyo
  3. Loss of HBs antigen in HBV genotype C infected patients, 2015/10/08, Without Invitation, Japanese, Tokyo
  4. Difference of intracellular responses by HBV genotype A and C infection in humanized mouse model, Masataka Tsuge, Nobuhiko Hiraga, Hiromi Abe, Daiki Miki, Michio Imamura, Hidenori Ochi, C Nelson Hayes, Kazuaki Chayama, AASLD 2015, 2015/11/17, Without Invitation, English, AASLD, San Francisco
  5. Nucleotide analogues improve interferon responsiveness in HBV-infected human hepatocytes, Masataka Tsuge Nobuhiko Hiraga Michio Imamura Hiromi Abe-Chayama Daiki Miki Hidenori Ochi C. Nelson Hayes Kazuaki Chayama, APASL annual meeting 2016, 2016/02/21, Without Invitation, Japanese, The Asian Pacific Association for the Study of the Liver, Tokyo
  6. Evaluation of antiviral effects of a novel site-specific pegylated interferon beta using humanized mouse model, Masataka Tsuge Takuro Uchida Hiromi Kan Hiromi Abe-Chayama Daiki Miki Michio Imamura Hidenori Ochi C Nelson Hayes Reiko Shimozono Tomokatsu Iwamura Hideki Narumi Tomohiko Suzuki Mie Kainoh Tadatsugu Taniguchi Kazuaki Chayama, AASLD, 2016/11/14, Without Invitation, English
  7. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agent therapy, Nagaoki Y Aikata H Kobayashi T Kawaoka T Tsuge M Hiramatsu A Imamura M Kawakami Y Chayama K, The 12th JSH Single Topic Conference, 2016/09/22, Without Invitation, Japanese
  8. Comparison of 18F-FDG PET-CT and Gd-EOB-DTPA-enhanced MRI for prediction of microvascular invasion and outcome after curative resection for early-stage hepatocellular carcinoma, Kobayashi T Aikata H Daijo K Teraoka Y Nakamura Y Morio K Nagaoki Y Kawaoka T Tsuge M Hiramatsu A Imamura M Kawakami Y Chayama K, AASLD2016, 2016/11/11, Without Invitation, Japanese
  9. Analysis of the effect on HBV by genome editing using CRISPR/Cas9 system, Masaki K Abe-Chayama H Sakuma T Tsuge M Imamura M Hayes CN Aikata H Yamamoto T Chayama K, AASLD2016, 2016/11/11, Without Invitation, Japanese
  10. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy, Nagaoki Y Aikata H Kawaoka T Tsuge M Hiramatsu A Imamura M Kawakami Y Chayama K, AASLD2016, 2016/11/11, Without Invitation, Japanese
  11. Involvement of type 4 porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, Nakahara T Hyogo H Ono A Nagaoki Y Kawaoka T Miki D Tsuge M Hiraga N Hayse CN Hiramatsu A Imamura M Kawakami Y Aikata H Ochi H Abe-Chayama H Furusho H Shintani T Chayama K, AASLD2016, 2016/11/11, Without Invitation, Japanese
  12. Reduction of intrahepatic cccDNA levels permits to regulate HBV replication after cessation of the treatment in human hepatocyte chimeric mice, Uchida T Imamura M Kan H Hiraga N Tsuge M Abe-Chayama H Aikata H Hayes CN Ishida Y Tateno C Chayama K, AASLD2016, 2016/11/15, Without Invitation, Japanese
  13. Change of antiviral effects by interferon with / without nucleoside analogue treatment, 2017/10/12, Without Invitation, Japanese
  14. HBV up-regulates IL8 expression via ER stress and leads to suppress interferon responsiveness, Masataka Tsuge, Nobuhiko Hiraga Takuro Uchida Eisuke Murakami Hiromi Abe-Chayama Daiki Miki Michio Imamura Yoshiiku Kawakami Hiroshi Aikata Hidenori Ochi C Nelson Hayes Kazuaki Chayama, AASLD 2017, 2017/10/23, Without Invitation, English
  15. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, AASLD 2017, 2017/10/20, Without Invitation, English
  16. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy, 2017/10/22, Without Invitation, English
  17. Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, AASLD 2017, 2017/10/22, Without Invitation, English
  18. TARDBP regulates HBV transcription and replication through interaction with the core promoter, AASLD 2017, 2017/10/22, Without Invitation, English
  19. Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model, AASLD 2017, 2017/10/22, Without Invitation, English
  20. Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice, AASLD 2017, 2017/10/23, Without Invitation, English
  21. Regulation of the Hepatitis B virus gene expression and replication by the multi-functional protein TARDBP, Grace Naswa Makokha, Kazuaki Chayama, Hiromi Abe-Chayama, Masataka Tsuge, Takuro Uchida, Yuji Ishida, AASLD The Liver Meeting 2018, 2018/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  22. The influence of histone methyltransferase SUV39h1 on hepatitis B virus related hepatocarcinogenesis, Ken Tsushima, Masataka Tsuge, Takuro Uchida, Michio Imamura, Mitsutaka Osawa, Hiromi Abe-Chayama, Grace Naswa Makokha, Hiroshi Aikata, Kazuaki Chayama, AASLD The Liver Meeting 2018, 2018/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  23. Prevalence of NS5A Resistance Associated Variants in NS5A Inhibitor Treatment Failuresand an Effective Treatment for NS5A-P32 Deleted Hepatitis C Virus in Humanized Mice, Yuji Teraoka, Takuro Uchida, Michio Imamura, Mitutaka Osawa, Tomokazu Kawaoka, MasatakaTsuge, Hiromi Abe-Chayama, Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno and Kazuaki Chayama, AASLD The Liver Meeting 2018, 2018/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  24. Efficacy of Glecaprevir and Pibrentasvir Treatment for Hepatitis C Virus Drug Resistance-Associated Variants in Humanized Mice, Mitsutaka Osawa, Takuro Uchida, Michio Imamura, Yuji Teraoka, Masataka Tsuge, Hiromi Abe-Chayama, Grace Naswa Makokha, Hiroshi Aikata, Yuji Ishida, Chise Tateno and Kazuaki Chayama, AASLD The Liver Meeting 2018, 2018/11/09, Without Invitation, English, American Association for the Study of Liver Diseases
  25. Stereotactic Body Radiation Therapy Combined with Transcatheter ArterialChemoembolization for Small Hepatocellular Carcinoma, Hiroshi Aikata, Akira Hiramatsu, Masataka Tsuge, Tomokazu Kawaoka, Michio Imamura, Eisuke Murakami and Kazuaki Chayama, The Liver Meeting 2018, 2018/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  26. A Novel Jak3KORag2KO Chimeric Mouse Model for the Study of Hepatitis Virus Virology, Takuro Uchida, Michio Imamura, Yuji Ishida, Chise Tateno, Mitsutaka Osawa, Yuji Teraoka, Masataka Tsuge, Hiromi Abe-Chayama, Grace Naswa Makokha, Hiroshi Aikata and Kazuaki Chayama, AASLD The Liver Meeting 2018, 2018/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  27. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma afterHepatitis C Virus Eradication and Fibrosis Severity, Daiki Miki, Tomokazu Kawaoka, Nagaoki Yuko, Nelson Hayes, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Hiromi Abe-Chayama, Hidenori Ochi, Tatsuhiko Tsunoda and Kazuaki Chayama, The Liver Meeting 2018, 2018/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  28. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with RadioTherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major PortalVein Tumor Thrombus, Kenichiro Kodama, Hiroshi Aikata, Shinsuke Uchikawa, Tomokazu Kawaoka, Kazuaki Chayama, Masataka Tsuge, Takashi Nakahara, Michio Imamura, Akira Hiramatsu and Eisuke Murakami, The Liver Meeting 2018, 2018/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  29. Efficacy and Safety of Edoxaban for Treatment of Portal Vein Thrombosis in Patients withLiver Cirrhosis, Nagaoki Yuko, Hiroshi Aikata, Eisuke Murakami, Takashi Nakahara, Tomokazu Kawaoka, MasatakaTsuge, Akira Hiramatsu, Michio Imamura and Kazuaki Chayama, The Liver Meeting 2018, 2018/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco
  30. Analyses of HBsAg reduction in sequential versus add-on pegylated-interferon to nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B patients, Masataka Tsuge, Yumiko Tatsukawa, Kazuaki Chayama, JDDW 2018, 2018/11/02, Without Invitation, Japanese
  31. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic HBV infection, Masataka Tsuge, Motonobu Nomura, Takuro Uchida, Hiromi Abe-Chayama, Daiki Miki, Michio Imamura, Hiroshi Aikata, Grace Naswa Makokha, C. Nelson Hayes, Kazuaki Chayama, 7th Japan-Taiwan-Korea HBV Research Symposium, 2019/04/05, Without Invitation, English
  32. Analyses of HBsAg reduction in sequential versus add-on pegylated-interferon to nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B patients, Masataka Tsuge, PETM seminar, 2019/02/20, With Invitation, English, The Program for Experimental & Theoretical Modeling (PETM), Loyola University Chicago Medical Center, Maywood, IL, USA
  33. Experience of regorafenib treatment for the patients with hepatocellular carcinoma progressed after sorafenib, Asian Pacific Association for the Study of the Liver Single Topic Conference, 2018/05/11, Without Invitation, Japanese, Yokohama
  34. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and TACE refractory, Asian Pacific Association for the Study of the Liver Single Topic Conference, 2018/05/11, Without Invitation, English, The Asian Pacific Association for the Study of the Liver, Yokohama
  35. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, THE LIVER MEETING 2018, 2018/11/10, Without Invitation, English
  36. L-carnitine reduces muscle mass loss in patients with liver cirrhosis, IBD and Liver:East Meets West, 2018/09/07, Without Invitation, English
  37. Multiple genetic factors affecting nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-related hepatocellular carcinoma in the Japanese population, 11th AACR-JCA Joint Conference, 2019/02/10, Without Invitation, English
  38. Analysis of the association between HBV infection and long-term trends in intrahepatic gene expression, Masataka Tsuge, Ken Tsushima Nobuhiko Hiraga Takuro Uchida Michio Imamura C. Hayes Nelson Harel Dahari Susan L. Uprichard Kazuaki Chayama, International HBV meeting 2019, 2019/10/01, Without Invitation, English, Melbourne
  39. HBV infection and spread in HepG2-NTCP cells initiated by low MOI inoculation in the absence of PEG, Delaina May Karina Durso-Cain Yuji Ishida Masataka Tsuge Mikaru Yamao Chise Tateno Harel Dahari Kazuaki Chayama Susan L. Uprichard, International HBV meeting 2019, 2019/10/01, Without Invitation, English, Melbourne

Awards

  1. 2016/02/24, Young Investigator Award, The Asian Pacific Association for the Study of the Liver (APASL), Nucleotide analogues improve interferon responsiveness in HBV-infected human hepatocytes

Patented

  1. Patent, 2019/06/14

Works, etc.

  1. B型肝炎ウイルス感染に伴う肝発癌候補遺伝子の網羅的解析とそのメカニズムの解明, 2007/06, The Others
  2. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus., 2007/02, The Others
  3. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus., 2006/10, The Others

External Funds

Acceptance Results of Competitive Funds

  1. Research Program on Hepatitis, 2015/04/01, 2016/03/31
  2. Research Program on Hepatitis, 2015/04/01, 2016/03/31
  3. 2009
  4. 2012
  5. 2012
  6. 2010
  7. 2012
  8. KAKENHI, Basic research for clarifing the phathologic characteristics with HBV genotype A infection, 2012, 2013
  9. KAKENHI, 2015, 2017
  10. KAKENHI, 2015, 2017
  11. Research Program on Hepatitis , 2016/04/01, 2017/03/31
  12. Research Program on Hepatitis , 2016/04/01, 2017/03/31
  13. Bristol-Myers Squibb Cyber Grants, 2015, 2017
  14. 2017
  15. 2017
  16. 2016, 2016
  17. 2017
  18. 2017
  19. 2017
  20. 2017
  21. Fund for the Promotion of Joint International Research (Fostering Joint International Research), Association analysis between the suppression of interferon responsiveness by HBV infection and changes of gene expression in human hepatocytes, 2018/04/01, 2019
  22. KAKENHI, 2018/04/01, 2021/03/31
  23. 2018, 2019
  24. Research Program on Hepatitis , 2017/04/01, 2018/03/31
  25. Research Program on Hepatitis , 2017/04/01, 2018/03/31
  26. 2018/04/01, 2019/03/31
  27. 2018/04/01, 2019/03/31
  28. 2018/04/01, 2019/03/31
  29. Research Program on Hepatitis , 2018/04/01, 2019/03/31
  30. Research Program on Hepatitis , 2018/04/01, 2019/03/31
  31. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2018, 2020
  32. 2019, 2020
  33. Research Program on Hepatitis , 2019/04/01, 2020/03/31
  34. Research Program on Hepatitis , 2019/04/01, 2020/03/31
  35. Research Program on Hepatitis, 2020/04/01, 2021/03/31
  36. Research Program on Hepatitis, 2020/04/01, 2021/03/31

Social Activities

History as Peer Reviews of Academic Papers

  1. 2023, Biochemical and Biophysical Research Communications, Others, Reviewer, 1
  2. 2023, Medical Microbiology and Immunology, Others, Reviewer, 1
  3. 2023, PLoS Computational Biology, Others, Reviewer, 1
  4. 2023, PLoS Computational Biology, Others, Reviewer, 2
  5. 2023, Scientific Reports, Others, Reviewer, 1
  6. 2021, Journal of Gastroenterology, Editor, Associate editor, 29
  7. 2020, Journal of Gastroenterology, Editor, Associate editor, 21
  8. 2019, Journal of Gastroenterology, Editor, Associate editor, 20
  9. 2019, Clinical Journal of Gastroenterology, Editor, Associate editor, 4
  10. 2018, Clinical Journal of Gastroenterology, Editor, Associate editor, 22
  11. 2017, Clinical Journal of Gastroenterology, Editor, Associate editor, 18
  12. 2021, Journal of Gastroenterology, Others, Reviewer, 1
  13. 2021, Viruses, Others, Reviewer, 4
  14. 2021, Gene Reports, Others, Reviewer, 1
  15. 2021, Digestion, Others, Reviewer, 1
  16. 2021, Computational and Structural Biotechnology Journal, Others, Reviewer, 1
  17. 2021, Livers, Others, Reviewer, 1
  18. 2020, Immunological Medicine, Others, Reviewer, 1
  19. 2020, PLoS one, Others, Reviewer, 1
  20. 2020, Journal of Gastroenterology and Hepatology, Others, Reviewer, 3
  21. 2020, Therapeutic Advances in Gastroenterology, Others, Reviewer, 1
  22. 2020, Viruses, Others, Reviewer, 1
  23. 2020, Hepatology International, Others, Reviewer, 3
  24. 2020, International Journal of Clinical Oncology, Others, Reviewer, 1
  25. 2020, Journal of Gastroenterology, Others, Reviewer, 3
  26. 2020, Hepatology Research, Others, Reviewer, 4
  27. 2020, Internal Medicine, Others, Reviewer, 2
  28. 2020, Digestion, Others, Reviewer, 1
  29. 2020, Clinical Journal of Gastroenterology, Others, Reviewer, 1
  30. 2019, International Journal of Clinical Virology, Others, Reviewer, 1
  31. 2019, Journal of Virological Methods, Others, Reviewer, 1
  32. 2019, Lancet Gastroenterology and Hepatology, Others, Reviewer, 1
  33. 2019, Hepatology Research, Others, Reviewer, 3
  34. 2019, Journal of Gastroenterology and Hepatology, Others, Reviewer, 3
  35. 2019, Digestion, Others, Reviewer, 1
  36. 2019, Clinical Journal of Gastroenterology, Others, Reviewer, 1
  37. 2019, Journal of Gastroenterology, Others, Reviewer, 2
  38. 2019, Viruses, Others, Reviewer, 2
  39. 2019, International Journal of Cardiology, Others, Reviewer, 1
  40. 2019, PLosONE, Others, Reviewer, 1
  41. 2018, Hepatology Research, Others, Reviewer, 2
  42. 2018, Journal of Gastroenterology and Hepatology, Others, Reviewer, 2
  43. 2018, Open Medicine, Others, Reviewer, 1
  44. 2018, BMC Infectious Diseases, Others, Reviewer, 1
  45. 2018, Journal of Gastroenterology, Others, Reviewer, 2
  46. 2018, Clinical Journal of Gastroenterology, Others, Reviewer, 3
  47. 2018, Therapeutic Advances in Medical Oncology, Others, Reviewer, 1
  48. 2018, BMC Gastroenterology, Others, Reviewer, 1
  49. 2018, Expert Review of Gastroenterology & Hepatology, Others, Reviewer, 2
  50. 2018, Antiviral Research, Others, Reviewer, 1
  51. 2017, Hepatology Research, Others, Reviewer, 1
  52. 2017, Hepatology International, Others, Reviewer, 2
  53. 2017, PLOS ONE, Others, Reviewer, 1
  54. 2017, Clinical Journal of Gastroenterology, Others, Reviewer, 3
  55. 2017, Journal of Gastroenterology, Others, Reviewer, 2
  56. 2017, Journal of Viral Hepatitis, Others, Reviewer, 1
  57. 2017, Journal of Virological Methods, Others, Reviewer, 1
  58. 2017, BMC Infectious Diseases, Others, Reviewer, 1
  59. 2017, Internal Medicine, Others, Reviewer, 1
  60. 2016, Hepatology Research, Others, Reviewer, 3
  61. 2016, Journal of Gastroenterology, Others, Reviewer, 3
  62. 2016, Scientific Reports, Others, Reviewer, 1
  63. 2016, Journal of Gastroenterology and Hepatology, Others, Reviewer, 1
  64. 2016, Expert Review of Vaccines, Others, Reviewer, 1
  65. 2016, Hepatology International, Others, Reviewer, 1
  66. 2016, MEEGID, Others, Reviewer, 1
  67. 2016, Journal of Interferon and Cytokine Research, Others, Reviewer, 1
  68. 2016, Journal of Viral Hepatitis, Others, Reviewer, 1
  69. 2015, International Journal of Environmental Research and Public Health, Others, Reviewer, 1
  70. 2015, Journal of Gastroenterology, Others, Reviewer, 2
  71. 2015, Hepatology Research, Others, Reviewer, 3
  72. 2015, Hepatology International, Others, Reviewer, 1
  73. 2015, Journal of Gastroenterology and Hepatology, Others, Reviewer, 2
  74. 2015, Journal of Medical Virology, Others, Reviewer, 1
  75. 2014, Hepatology Research, Others, Reviewer, 4
  76. 2014, Internal Medicine, Others, Reviewer, 1
  77. 2014, Pharmacogenetics, Others, Reviewer, 1
  78. 2013, Hepatology Research, Others, Reviewer, 4
  79. 2013, Journal of Medical Virology, Others, Reviewer, 1
  80. 2013, Journal of Gastrenterology and Hepatology, Others, Reviewer, 1
  81. 2013, BioMed Research International, Others, Reviewer, 1
  82. 2013, Future Microbiology, Others, Reviewer, 1
  83. 2012, Hepatology Research, Others, Reviewer, 6
  84. 2012, Hiroshima Journal of Medical Science, Others, Reviewer, 1
  85. 2012, Journal of Medical Virology, Others, Reviewer, 1
  86. 2011, Hepatology Research, Others, Reviewer, 5
  87. 2021, Clinical Journal of Gastroenterology, Others, Reviewer, 1
  88. 2022, Journal of Gastroenterology, Others, Reviewer, 2
  89. 2022, Journal of Gastroenterology, Editor, Associate editor, 34
  90. 2023, Hepatology International, Others, Reviewer, 1